Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Expertise in Melanoma: HELP
Imanol Arozarena
Based on 13 articles published since 2009
(Why 13 articles?)
||||
Expertise Level
The expertise of Imanol Arozarena ranks in the
  • Top 0.33%
  • ... of 106,334 published authors worldwide on Melanoma
  • ... from 2009 through 2019
  • ... based on contributions to 13 articles on the topic.
Graphical view (beta)
Get your prestigious
Expert badge
similar to this:
 
Aliases Arozarena, Imanol   ·   Arozarena, I
Work Locations
Details
Most likely:    Instituto de Investigacion Sanitaria de Navarra      
2019
  • Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain. · Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. · Pubmed 31209265
2018
  • Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC)-Universidad de Cantabria, Santander, 39011, Spain. · Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, 28029, Spain. · Division of Cancer Studies, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, M13 9PL, UK. · Navarrabiomed-FMS IDISNA, Pamplona, Navarra, 31008, Spain. · Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, 37007, Spain. · Instituto de Biología Molecular y Celular del Cáncer, CSIC-Universidad de Salamanca, Salamanca, 37007, Spain. · Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA92093, USA. · Division of Cancer Studies, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, M13 9PL, UK. · Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC)-Universidad de Cantabria, Santander, 39011, Spain. · Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, 28029, Spain. · Pubmed 30185827
2017
  • Cancer Signalling Group, Navarrabiomed (Miguel Servet Foundation), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain. · Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, The University of Manchester, UK. · Pubmed 28196297
  • Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. · Translational Research Institute, The University of Queensland Diamantina Institute, The University of Queensland, Brisbane, Qld, Australia. · Discipline of Dermatology, University of Sydney, Sydney, NSW, Australia. · Navarrabiomed-Fundación Miguel Servet-Idisna, Pamplona, Spain. · Systems Biology Ireland, School of Medicine, UCD, Dublin 4, Ireland. · Department of Dermatology, Universitätsspital Zürich, University of Zurich, Zurich, Switzerland. · Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA. · Division of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK · Pubmed 28606996
Probable:    Universidad Publica de Navarra      
2019
  • Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain. · Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. · Pubmed 31209265
Probable:    Miscellaneous institutions in Santander      
2018
  • Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC)-Universidad de Cantabria, Santander, 39011, Spain. · Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, 28029, Spain. · Division of Cancer Studies, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, M13 9PL, UK. · Navarrabiomed-FMS IDISNA, Pamplona, Navarra, 31008, Spain. · Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, 37007, Spain. · Instituto de Biología Molecular y Celular del Cáncer, CSIC-Universidad de Salamanca, Salamanca, 37007, Spain. · Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA92093, USA. · Division of Cancer Studies, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, M13 9PL, UK. · Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC)-Universidad de Cantabria, Santander, 39011, Spain. · Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, 28029, Spain. · Pubmed 30185827
Show More
Specific Interests

In the titles of their published articles, experts often reveal their very specific interests.

Here are the titles of the 10 most recent articles (out of 13 total) written by Imanol Arozarena about Melanoma:

  • Phenotype plasticity as enabler of melanoma progression and therapy resistance. 2019
  • RAS at the Golgi antagonizes malignant transformation through PTPRκ-mediated inhibition of ERK activation. 2018
  • Targeting invasive properties of melanoma cells. 2017
  • Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. 2017
  • An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. 2017
  • Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. 2016
  • Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy. 2015
  • MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide. 2015
  • Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. 2014
  • Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. 2013
Show List of Full Article Records
Google Searches

Learn more about Imanol Arozarena using the ready-made Google searches below.
This is essential! -- Publications never tell the whole story!

General Search:
Instituto de Investigacion Sanitaria de Navarra
Universidad Publica de Navarra
Miscellaneous institutions in Santander
Affiliation Timeline
Click for institutional directory in table below. (Not always available.)
What is this?
Instituto de Investigacion Sanitaria de Navarra
2019
  • Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain. · Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. · Pubmed 31209265
2018
  • Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC)-Universidad de Cantabria, Santander, 39011, Spain. · Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, 28029, Spain. · Division of Cancer Studies, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, M13 9PL, UK. · Navarrabiomed-FMS IDISNA, Pamplona, Navarra, 31008, Spain. · Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, 37007, Spain. · Instituto de Biología Molecular y Celular del Cáncer, CSIC-Universidad de Salamanca, Salamanca, 37007, Spain. · Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA92093, USA. · Division of Cancer Studies, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, M13 9PL, UK. · Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC)-Universidad de Cantabria, Santander, 39011, Spain. · Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, 28029, Spain. · Pubmed 30185827
2017
  • Cancer Signalling Group, Navarrabiomed (Miguel Servet Foundation), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain. · Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, The University of Manchester, UK. · Pubmed 28196297
  • Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. · Translational Research Institute, The University of Queensland Diamantina Institute, The University of Queensland, Brisbane, Qld, Australia. · Discipline of Dermatology, University of Sydney, Sydney, NSW, Australia. · Navarrabiomed-Fundación Miguel Servet-Idisna, Pamplona, Spain. · Systems Biology Ireland, School of Medicine, UCD, Dublin 4, Ireland. · Department of Dermatology, Universitätsspital Zürich, University of Zurich, Zurich, Switzerland. · Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA. · Division of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK · Pubmed 28606996
Universidad Publica de Navarra
2019
  • Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain. · Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. · Pubmed 31209265
Miscellaneous institutions in Santander
2018
  • Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC)-Universidad de Cantabria, Santander, 39011, Spain. · Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, 28029, Spain. · Division of Cancer Studies, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, M13 9PL, UK. · Navarrabiomed-FMS IDISNA, Pamplona, Navarra, 31008, Spain. · Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, 37007, Spain. · Instituto de Biología Molecular y Celular del Cáncer, CSIC-Universidad de Salamanca, Salamanca, 37007, Spain. · Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA92093, USA. · Division of Cancer Studies, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, M13 9PL, UK. · Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC)-Universidad de Cantabria, Santander, 39011, Spain. · Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, 28029, Spain. · Pubmed 30185827
Manchester Academic Health Science Centre
2017
  • Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. · Translational Research Institute, The University of Queensland Diamantina Institute, The University of Queensland, Brisbane, Qld, Australia. · Discipline of Dermatology, University of Sydney, Sydney, NSW, Australia. · Navarrabiomed-Fundación Miguel Servet-Idisna, Pamplona, Spain. · Systems Biology Ireland, School of Medicine, UCD, Dublin 4, Ireland. · Department of Dermatology, Universitätsspital Zürich, University of Zurich, Zurich, Switzerland. · Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA. · Division of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK · Pubmed 28606996
  • Manchester Cancer Research Centre, Faculty of Biology, Medicine, and Health, School of Medical Sciences, Division of Molecular and Clinical Cancer Studies, The University of Manchester, Manchester M13 9PT, England, UK. · Department of Molecular and Translational Medicine, Section of Pathology, University of Brescia, 25123 Brescia, Italy. · Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy. · Division of Oncology, MedImmune Ltd, Cambridge CB21 6GH, England, UK. · Edinburgh Cancer Research Centre, Medical Research Council Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh EH4 2XR, Scotland, UK. · Department of Dermatology, University Hospital Zürich, 8091 Zürich, Switzerland. · Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA 02114. · Division of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030. · Medical Research Council London Institute of Medical Sciences, London W12 0NN, England, UK. · Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London W12 0NN, England, UK. · Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110. · Manchester Cancer Research Centre, Faculty of Biology, Medicine, and Health, School of Medical Sciences, Division of Molecular and Clinical Cancer Studies, The University of Manchester, Manchester M13 9PT, England, UK · Pubmed 28450382
2016
  • Manchester Cancer Research Centre, Wellcome Trust Centre for Cell-Matrix Research, The University of Manchester, Michael Smith Building, Oxford Road, Manchester, M13 9PT, UK. · Molecular Oncology Group, CRUK Manchester Institute for Cancer Research, Manchester Cancer Research Centre, Wilmslow Road, Manchester, M20 4BX, UK. · Department of Dermatology, UniversitätsSpital Zürich, University of Zürich, Gloriastrasse 31, 8091 Zurich, Switzerland. · Department of Medicine, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114-2696, USA. · Divison of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX 77030, USA. · Manchester Cancer Research Centre, Wellcome Trust Centre for Cell-Matrix Research, The University of Manchester, Michael Smith Building, Oxford Road, Manchester, M13 9PT, UK. Electronic address: · Pubmed 26977879
2015
  • Manchester Cancer Research Centre, Wellcome Trust Centre for Cell Matrix Research, Faculty of Life Sciences, The University of Manchester, Manchester, UK. · Pubmed 25818589
  • Manchester Cancer Research Centre, The University of Manchester, Michael Smith Building, Oxford Road, Manchester, United Kingdom. · Edinburgh Cancer Research UK Centre and MRC Institute of Genetics and Molecular Medicine, Western General Hospital, University of Edinburgh, Edinburgh, United Kingdom. · Divisions of Molecular Pathology and Cancer Therapeutics, Institute of Cancer Research, Sutton, United Kingdom. · Centre for Occupational and Environmental Health, The University of Manchester, Stopford Building, Manchester, United Kingdom. · Manchester Cancer Research Centre, The University of Manchester, Michael Smith Building, Oxford Road, Manchester, United Kingdom. · Pubmed 25777962
2014
  • Manchester Cancer Research Centre, The University of Manchester, Michael Smith Building, Oxford Road, Manchester M13 9PT, UK. · Pubmed 24941944
2011
  • Molecular Cancer Studies, Wellcome Trust Centre for Cell Matrix Research, Faculty of Life Sciences, University of Manchester, Manchester, UK. · Pubmed 21577209
2013
  • Molecular Cancer Studies, Wellcome Trust Centre for Cell Matrix Research, University of Manchester, Oxford Rd, Manchester, UK. · Pubmed 23250956
  • Molecular Cancer Studies, Wellcome Trust Centre for Cell Matrix Research, University of Manchester, Manchester, UK. · Pubmed 22310287
University of London
2011
  • The Institute of Cancer Research, Signal Transduction Team, Section of Cell and Molecular Biology, 237 Fulham Road, London SW3 6JB, UK. · Pubmed 21215707
Yearly article counts 11312120200
Remember this Person You can save this page -- like a bookmark -- so it's remembered for you on the Expertscape "Saved Pages" page, which is always easily available from the page-top menu bar throughout the site.